-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $72

Benzinga·06/29/2026 13:32:50
Listen to the news
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $59 to $72.